Andrew M. Scott
YOU?
Author Swipe
View article: Theranostics and nuclear medicine practice in Asia-Pacific: an IAEA regional study
Theranostics and nuclear medicine practice in Asia-Pacific: an IAEA regional study Open
The Asia-Pacific region, comprising more than half of the world's population, includes both developed and developing nations. Understanding the current status of nuclear medicine (NM) and theranostics in this dynamic region is essential fo…
View article: CTNI-25. MULTI-SITE, PROSPECTIVE TRIAL EVALUATING FET-PET IN GLIOBLASTOMA (FIG) STUDY (TROG 18.06): CENTRAL NUCLEAR MEDICINE AND RADIATION ONCOLOGY REVIEW OF FET-PET BIOLOGIC TARGET VOLUME DELINEATION FOR RADIATION PLANNING
CTNI-25. MULTI-SITE, PROSPECTIVE TRIAL EVALUATING FET-PET IN GLIOBLASTOMA (FIG) STUDY (TROG 18.06): CENTRAL NUCLEAR MEDICINE AND RADIATION ONCOLOGY REVIEW OF FET-PET BIOLOGIC TARGET VOLUME DELINEATION FOR RADIATION PLANNING Open
BACKGROUND The prospective multi-site trial evaluating O-(2-[18F]-fluoroethyl)-L-tyrosine Positron Emission Tomography (FET-PET) in Glioblastoma (FIG) study is currently recruiting. This abstract aims to evaluate the impact of full central…
View article: Development of automated radiosynthesis of [18F]FDG on the iPHASE MultiSyn radiosynthesizer for routine clinical application
Development of automated radiosynthesis of [18F]FDG on the iPHASE MultiSyn radiosynthesizer for routine clinical application Open
View article: Radioligand Therapy in Cancer Management: A Global Perspective
Radioligand Therapy in Cancer Management: A Global Perspective Open
Radioligand therapy (RLT) is a targeted treatment modality that combines a tumour-specific ligand with a therapeutic radionuclide. Once administered, the radiopharmaceutical binds selectively to cancer-associated targets, delivering cytoto…
View article: Characterisation of mAb104 Antibody–Drug Conjugates Targeting a Tumour-Selective HER2 Epitope
Characterisation of mAb104 Antibody–Drug Conjugates Targeting a Tumour-Selective HER2 Epitope Open
Background: The novel anti-HER2 antibody 104 (mAb104) targets a unique tumour-specific epitope, lacks normal tissue binding and can internalise into tumour cells, thus supporting its development into antibody drug conjugates (ADCs). Method…
View article: Figure S5 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Figure S5 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
mAb104 does not affect EGF-independent (left) EGF-dependent (right) downstream signaling in the MAPK and AKT pathways (A, B) SK-BR-3 and (C, D) BT474 cells in-vitro as monotherapy or in combination with trastuzumab or pertuzumab. Cells inc…
View article: Figure S8 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Figure S8 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
The effect of mAb104 treatment on the HER2 and MAPK/mTOR signaling pathway in NCI-N87 tumors after (left) week 1 and (right) week 3 of treatment. Data representative of two independent experiments.
View article: Figure S2 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Figure S2 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
FACS analysis using 10μg/mL antibodies confirming small shift in mAb104 binding in high HER2-expressing (A) NCI-N87, (B) BT-474, (C) SK-BR-3 and (D) NCI-H2170 but not in low HER2-expressing (E) NCI-H838, (F) NCI-H522 and (G) NCI-H1650 cell…
View article: Supplementary Table 1 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Supplementary Table 1 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
Supplementary Table 1
View article: Data from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Data from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
We generated a novel HER2 mAb104, which binds to an epitope in domain II of HER2 that is conformationally exposed in tumors in response to HER2 amplification or activation but is not accessible to antibody binding in normal tissues.…
View article: Supplementary Table 2 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Supplementary Table 2 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
Supplementary Table 2
View article: Figure S4 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Figure S4 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
The effect of mAb104, trastuzumab and pertuzumab monotherapy (left) or in combination (right) on the growth of (A) NCI-N87, (B) BT-474, (C) SK-BR-3 and (D) OE-19 in-vitro as measured by MTS assay. Cells were incubated with antibodies or is…
View article: Figure S3 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Figure S3 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
Immunohistochemical staining with mAb104 and anti-HER2 antibody in (x400) normal (A) brain, (B) large bowel, (C) renal tissue, (D) lung and tumor tissues (E) adenocarcinoma bowel, (F) adenomacarcinoma lung, (G) squamous carcinoma lung, (H)…
View article: Figure S6 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Figure S6 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
mAb104 does not affect EGF-independent (left) EGF-dependent (right) downstream signaling in the MAPK and AKT pathways (A, B) NCI-N87 and (C, D) OE-19 cells in-vitro as monotherapy or in combination with trastuzumab or pertuzumab. Cells inc…
View article: Supplementary Data from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Supplementary Data from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
Supplementary Data
View article: Figure S7 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Figure S7 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
mAb104 binding and anti-tumor effects in gastric OE-19 cancer xenograft (A) Binding of 10μg/mL of Trastuzumab, Pertuzumab and mAb104 (green) to OE-19 cells. B, Mice bearing OE-19 xenografts (n = 5) were treated with Trastuzumab, Per…
View article: Figure S1 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Figure S1 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
Comparative binding of mAb104, mAb105, mAb106 and mAb107 to the HER2 extracellular domain, circularized and linear peptide immunogens which the antibodies were generated against, or control irrelevant peptide, using an ELISA based assay. S…
View article: MR-Guided Adaptive Radiotherapy for Glioblastoma: Clinical Outcomes and Quality of Life in an Australian Cohort
MR-Guided Adaptive Radiotherapy for Glioblastoma: Clinical Outcomes and Quality of Life in an Australian Cohort Open
View article: ARTnet Perspectives and Contributions to Theranostics
ARTnet Perspectives and Contributions to Theranostics Open
Theranostics is a rapidly growing field, providing new therapeutic options for cancer patients. Clinical trials have a key role in establishing the efficacy and safety of new treatments and determining impact on patient care. Multicenter c…
View article: Theranostics Implementation: Opportunities and Challenges
Theranostics Implementation: Opportunities and Challenges Open
View article: Implementation of Radiotheranostics: Challenges, Barriers, and IAEA-Driven Strategies for Sustainable Access
Implementation of Radiotheranostics: Challenges, Barriers, and IAEA-Driven Strategies for Sustainable Access Open
Radiotheranostics represent a cutting-edge advancement in the management of noncommunicable diseases, integrating diagnostic imaging with targeted radiotherapy in a single, personalized approach. Over the past decade, the field has gained …
View article: Monte Carlo prediction and experimental characterisation of long-lived waste byproducts arising from cyclotron production of zirconium-89 utilising a commercially available yttrium foil
Monte Carlo prediction and experimental characterisation of long-lived waste byproducts arising from cyclotron production of zirconium-89 utilising a commercially available yttrium foil Open
Zirconium-89 is presently undergoing pre-clinical investigation for its potential application as a positron emission tomography (PET) theranostic radioisotope. A critical consideration in the increasing number of trials and eventual clinic…
View article: Telomere length measures in the Northern Ireland cohort for the longitudinal study of ageing (NICOLA)
Telomere length measures in the Northern Ireland cohort for the longitudinal study of ageing (NICOLA) Open
View article: The genetic basis of natural variation in sociability
The genetic basis of natural variation in sociability Open
Sociability, defined as individuals’ tendencies to affiliate with conspecifics, is widespread among animals, including species not traditionally categorized as social. A few studies have documented a positive association between sociabilit…
View article: Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery
Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery Open
The efficacy of chimeric antigen receptor (CAR) T cell therapy in solid tumours is limited by immunosuppression and antigen heterogeneity1-3. To overcome these barriers, 'armoured' CAR T cells, which secrete proinflammatory cyto…
View article: T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial Open
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are highly radiosensitive with immune-driven abscopal responses reported. Programmed cell death 1/programmed cell death ligand 1 (PD-L1) inhibitors are relatively ineffecti…
View article: Author Correction: RANO criteria for response assessment of brain metastases based on amino acid PET imaging
Author Correction: RANO criteria for response assessment of brain metastases based on amino acid PET imaging Open
View article: 230 | TREATMENT OF NEWLY‐DIAGNOSED FOLLICULAR LYMPHOMA WITH RITUXIMAB, GOLCADOMIDE +/‐ NIVOLUMAB‐ INTERIM ANALYSIS OF THE PHASE II TOP‐FLOR STUDY
230 | TREATMENT OF NEWLY‐DIAGNOSED FOLLICULAR LYMPHOMA WITH RITUXIMAB, GOLCADOMIDE +/‐ NIVOLUMAB‐ INTERIM ANALYSIS OF THE PHASE II TOP‐FLOR STUDY Open
View article: Correction to: Guiding principles on the education and practice of theranostics
Correction to: Guiding principles on the education and practice of theranostics Open
View article: Monte Carlo prediction and experimental characterisation of long-lived waste byproducts arising from cyclotron production of zirconium-89 utilising a commercially available yttrium foil
Monte Carlo prediction and experimental characterisation of long-lived waste byproducts arising from cyclotron production of zirconium-89 utilising a commercially available yttrium foil Open
Zirconium-89 is presently undergoing pre-clinical investigation for its potential application as a positron emission tomography (PET) theranostic radioisotope. A critical consideration in the increasing number of trials and eventual clinic…